Budget Amount *help |
¥4,160,000 (Direct Cost: ¥3,200,000、Indirect Cost: ¥960,000)
Fiscal Year 2014: ¥1,690,000 (Direct Cost: ¥1,300,000、Indirect Cost: ¥390,000)
Fiscal Year 2013: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
Outline of Final Research Achievements |
We have previously observed that the macrophages (Mf) infiltrated in glomeruli showed higher MRP8 positivity compared to those in interstitium in diabetic nehropathy. TLR4 deletion did not ameliorate the worsening of diabetic nephropathy nor glomerular MRP8 upregulation by angiotensin II infusion. Besides, MRP8 upregulation in Mf stimulated with mesangilal cell-cultured medium was not altered by TLR4 antagonist. Taken together, MRP8 could become a novel therapeutic target rather than blockade of TLR4 especially in the pathogenesis associated with intraglomerular cross talk.
|